Who Is at Higher Risk?

• Adults 40–60 years old.
• Smokers and individuals with occupational silica exposure.
• Patients on long‑term propylthiouracil or similar drugs.

Diagnosis

Because GPA mimics infections, malignancy, and other vasculitides, a systematic approach is essential.

Clinical Evaluation

1. Detailed history (symptom chronology, occupational exposures, medication list).
2. Comprehensive physical exam (ENT, pulmonary, renal, skin, neurologic).

Laboratory Tests

• ANCA testing – indirect immunofluorescence (IIF) and ELISA for PR3‑ANCA (c‑ANCA) and MPO‑ANCA (p‑ANCA). Positive PR3‑ANCA is highly suggestive of GPA.
• Complete blood count (CBC) – anemia, leukocytosis.
• Serum creatinine & eGFR – assess kidney function.
• Urinalysis – hematuria, proteinuria, red‑cell casts.
• Inflammatory markers – ESR, CRP (usually elevated).

Imaging Studies

• Chest X‑ray or CT scan – nodules, cavitary lesions, infiltrates.
• Sinus CT – mucosal thickening, bony destruction.
• MRI for CNS or orbital involvement if indicated.

Biopsy (Gold Standard)

Histopathologic confirmation shows necrotizing granulomatous inflammation with vasculitis. Tissue sources include:

• Nasopharyngeal or sinus mucosa.
• Kidney (renal biopsy) – especially when glomerulonephritis is suspected.
• Skin or lung lesions.

Biopsy is required when the diagnosis is uncertain or before initiating potent immunosuppressive therapy.

Classification Criteria

The 2022 ACR/EULAR Classification Criteria for GPA assign points for clinical features, ANCA status, and histology, yielding a score ≥5 for classification. Clinicians use these criteria alongside judgment.

Treatment Options

Early, aggressive treatment dramatically improves survival—five‑year survival >90 % compared with <30 % pre‑therapy (Mayo Clinic). Treatment consists of two phases: induction (rapid disease control) and maintenance (preventing relapse).

Induction Therapy

• Glucocorticoids – high‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone (500‑1000 mg/day for 3 days) for severe disease.
• Immunosuppressive agents:
  • Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly ×4 or 1 g on days 1 & 15; preferred for many patients (RAVE trial, NEJM 2010).
  • Cyclophosphamide – oral (2 mg/kg/day) or IV pulses (15 mg/kg every 2‑3 weeks) – traditional standard, especially for life‑threatening renal or pulmonary disease.
• Adjunctive plasmapheresis may be considered for rapidly progressive glomerulonephritis or severe pulmonary hemorrhage (PEXIVAS trial, NEJM 2020).

Maintenance Therapy

After achieving remission (usually 4–6 months), the regimen is de‑escalated:

• Rituximab – 500 mg every 6 months for 2‑4 years.
• Azathioprine (2 mg/kg/day) or Mycophenolate mofetil (1‑1.5 g twice daily) as alternative agents.
• Low‑dose glucocorticoids (≤10 mg/day) tapered over months.

Supportive & Symptomatic Care

• Prophylaxis against opportunistic infections (e.g., trimethoprim‑sulfamethoxazole for Pneumocystis jirovecii).
• Vaccinations – influenza, pneumococcal, COVID‑19 (non‑live vaccines preferred).
• Bone health – calcium, vitamin D, bisphosphonates if steroids prolonged.
• Management of hypertension, diabetes, and dyslipidemia to protect kidneys and heart.

Lifestyle & Non‑Pharmacologic Measures

• Smoking cessation – reduces pulmonary complications.
• Stress‑management techniques (mindfulness, yoga) – may help immune modulation.
• Regular aerobic exercise (as tolerated) to maintain cardiovascular fitness.

Living with Granulomatosis with Polyangiitis

GPA is a chronic condition that requires ongoing self‑monitoring and collaboration with a multidisciplinary team (rheumatology, nephrology, ENT, pulmonology, and primary care).

Daily Management Tips

1. Medication adherence – use a pillbox or smartphone reminders; never stop steroids abruptly.
2. Symptom diary – record fevers, cough, urinary changes, sinus symptoms, and any new skin lesions.
3. Lab & imaging follow‑up – keep scheduled appointments for CBC, creatinine, ANCA titers, and imaging as directed.
4. Infection vigilance – seek prompt care for fevers, persistent cough, or urinary symptoms.
5. Hydration & renal protection – drink adequate fluids; avoid NSAIDs if kidneys are compromised.
6. Dental & ENT care – regular dental cleanings and ENT examinations to prevent sinus complications.

Psychosocial Support

• Consider joining a GPA support group (e.g., Vasculitis Foundation).
• Access counseling or therapy to cope with chronic illness stress.
• Utilize patient portals to stay connected with your care team.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, risk reduction strategies include:

• Avoiding known triggers – minimize silica dust exposure, stop smoking, and discuss alternative medications if you require drugs linked to ANCA vasculitis.
• Prompt treatment of sinus infections – reduces chronic inflammation that could trigger disease activity.
• Vaccination – keeps infections that could exacerbate autoimmune activity at bay.

Complications

If left untreated or inadequately controlled, GPA can lead to organ‑specific and systemic complications:

• Renal failure – rapidly progressive glomerulonephritis may require dialysis or transplantation.
• Permanent lung damage – fibrosis, cavitary lesions, or life‑threatening hemorrhage.
• Hearing loss or chronic sinus disease requiring surgery.
• Peripheral neuropathy – can cause lasting weakness or numbness.
• Ocular complications – scleritis or vision loss.
• Increased infection risk – due to immunosuppressive therapy.
• Medication toxicity – cyclophosphamide (bladder toxicity, infertility) or steroids (osteoporosis, diabetes).

When to Seek Emergency Care

References: Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). Link. CDC. Vasculitis. PDF. NIH. ANCA‑Associated Vasculitis. Link. RAVE Trial – NEJM 2010; PEXIVAS Trial – NEJM 2020; WHO. Autoimmune disease fact sheet 2023.